Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Comment: Fixed-duration venetoclax plus obinutuzumab in patients with CLL and comorbidities

Prof Anton Hagenbeek - University of Amsterdam, Amsterdam, The Netherlands

Comment: Fixed-duration venetoclax plus obinutuzumab in patients with CLL and comorbidities ( Prof Anton Hagenbeek - University of Amsterdam, Amsterdam, The Netherlands )

ASCEND: Acalabrutinib versus rituximab with idelalisib or bendamustine in relapsed or refractory CLL

Prof Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy

$ASCEND: Acalabrutinib versus rituximab with idelalisib or bendamustine in relapsed or refractory CLL ( Prof Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy )$

Novel immunotherapy 5F9 plus rituximab well tolerated with rapid and durable responses in R/R DLBCL and indolent lymphoma

Dr Mark Roschewski - National Cancer Institute, Bethesda, USA

Novel immunotherapy 5F9 plus rituximab well tolerated with rapid and durable responses in R/R DLBCL and indolent lymphoma ( Dr Mark Roschewski - National Cancer Institute, Bethesda, USA )

Acalabrutinib monotherapy shows significant benefit in relapsed or refractory chronic lymphocytic leukaemia

Dr Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy

$Acalabrutinib monotherapy shows significant benefit in relapsed or refractory chronic lymphocytic leukaemia ( Dr Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy )$

D-VTd in induction prior to and consolidation after ASCT improves PFS and depth of response with acceptable safety

Prof Philippe Moreau - Chu Nantes, Nantes, France

D-VTd in induction prior to and consolidation after ASCT improves PFS and depth of response with acceptable safety ( Prof Philippe Moreau - Chu Nantes, Nantes, France )

Imetelstat provides durable transfusion independence in heavily transfused non-del(5q) LR-MDS R/R to ESAS

Dr Pierre Fenaux - Hôpital St Louis and Paris University, Paris, France

Imetelstat provides durable transfusion independence in heavily transfused non-del(5q) LR-MDS R/R to ESAS ( Dr Pierre Fenaux - Hôpital St Louis and Paris University, Paris, France )

Most pregnancies in CML patients resulted in normal childbirth: Analysis of 305 cases of the European Leukemia Net registry

Dr Ekaterina Chelysheva - National Research Center for Hematology, Moscow, Russian Federation

Most pregnancies in CML patients resulted in normal childbirth: Analysis of 305 cases of the European Leukemia Net registry ( Dr Ekaterina Chelysheva - National Research Center for Hematology, Moscow, Russian Federation )

Venetoclax plus obinutuzumab improves PFS and MRD-negativity in patients with previously untreated CLL and comorbidities

Dr Kirsten Fischer - Uniklinik Köln, Cologne, Germany

Venetoclax plus obinutuzumab improves PFS and MRD-negativity in patients with previously untreated CLL and comorbidities ( Dr Kirsten Fischer - Uniklinik Köln, Cologne, Germany )

Intervention for AML patients with MRD can result in improved survival

Dr Christopher Hourigan - Laboratory of Myeloid Malignancies, National Heart, Lung, and Blood Institute, NIH, Bethesda, USA

Intervention for AML patients with MRD can result in improved survival ( Dr Christopher Hourigan - Laboratory of Myeloid Malignancies, National Heart, Lung, and Blood Institute, NIH, Bethesda, USA )

DORA: Using olaparib alone or with durvalumab in platinum responsive advanced triple-negative breast cancer

Dr Tira Tan - National Cancer Centre, Singapore

DORA: Using olaparib alone or with durvalumab in platinum responsive advanced triple-negative breast cancer ( Dr Tira Tan - National Cancer Centre, Singapore )

EMBRACA: Results of talazoparib vs chemotherapy relative to prior CT in patients with advanced breast cancer

Dr Johannes Ettl - Technical University, Munich, Germany

EMBRACA: Results of talazoparib vs chemotherapy relative to prior CT in patients with advanced breast cancer ( Dr Johannes Ettl - Technical University, Munich, Germany )

ABC-06 results: Second-line ASC mFOLFOX chemotherapy for biliary tract cancer

Dr Angela Lamarca - The Christie NHS Foundation Trust, Manchester, UK

ABC-06 results: Second-line ASC mFOLFOX chemotherapy for biliary tract cancer ( Dr Angela Lamarca - The Christie NHS Foundation Trust, Manchester, UK )

More from ecancer